Table 1.
Characteristics of patients with FSGS from five independent cohort studies
| Characteristic | NEPTUNE (n=123) | FSGS-CT (n=138) | NACI (n=34) | NS-REG (n=111) | C-PROBE (n=60) |
|---|---|---|---|---|---|
| Age (Median, IQR) | 30 (14–47) | 15 (11–23) | 19 (14–29) | 34 (20–53) | 41 (21–54) |
| Pediatric (<18) | 44 (36) | 93 (67) | 12 (35) | 18 (16) | 13 (22) |
| Adult (18+) | 79 (64) | 45 (33) | 22 (65) | 93 (84) | 47 (78) |
| Sex, n (%) | |||||
| Female | 51 (41) | 65 (47) | 17 (50) | 58 (52) | 25 (42) |
| Male | 72 (59) | 73 (53) | 17 (50) | 53 (48) | 35 (58) |
| Race, n (%) | |||||
| Asian/Asian American | 9 (7) | 3 (2) | 8 (24) | 4 (4) | 0 (0) |
| Black | 34 (23) | 53 (38) | 8 (24) | 26 (23) | 26 (43) |
| White | 66 (54) | 78 (57) | 17 (50) | 74 (67) | 31 (52) |
| Other | 14 (11) | 4 (3) | 1 (3) | 7 (6) | 3 (5) |
| Hypertension at baseline, n (%) | 75 (61) | 80 (58) | 18 (56) | 30 (27) | 51 (85) |
| Urine protein-to-creatinine ratio at entry, median (IQR) | 4.2 (2.1–8.1) | 4.0 (2.2–8.3) | 3.6 (1.9–7.5) | 3.4 (1.7–7.2) | 2.4 (1.6–7.4) |
| Nephrotic range proteinuria at entry (>3.5) | 71 (58) | 77 (56) | 17 (50) | 53 (48) | 23 (38) |
| eGFR at entry, median (IQR) | 77 (49–101) | 112 (76–180) | 71 (43–122) | 66 (41–96) | 72 (50–109) |
| ESRD/50% reduction in eGFR during follow-up, n (%) | 31 (25) | 40 (29) | 7 (21) | 55 (50) | 10 (17) |
Categoric variables are displayed as frequency (percent) and continuous variables as median (25th, 75th percentile). NEPTUNE, Nephrotic Syndrome Study Network; FSGS-CT, The National Institutes of Health-funded FSGS Clinical Trial; NACI, The NephCure Accelerating Cures Institute; NS-REG, University of Michigan Nephrotic Syndrome Registry; C-PROBE, The Clinical Phenotyping Resource and Biobank Core; IQR, interquartile range.